Homologous repair deficiency score for identifying breast cancers with defective DNA damage response

Breast cancer (BC) in patients with germline mutations of BRCA1/BRCA2 are associated with benefit from drugs targeting DNA damage response (DDR), but they account for only 5–7% of overall breast cancer. To define the characteristics of these tumors and also to identify tumors without BRCA mutation b...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Ahrum, Kim, Kwangsoo, Jeong, Kyeonghun, Choi, Seongmin, Kim, Seongyeong, Suh, Koung Jin, Lee, Kyung-Hun, Kim, Sun, Im, Seock-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385153/
https://www.ncbi.nlm.nih.gov/pubmed/32719318
http://dx.doi.org/10.1038/s41598-020-68176-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385153/
https://www.ncbi.nlm.nih.gov/pubmed/32719318
http://dx.doi.org/10.1038/s41598-020-68176-y

Ejemplares similares